Drugs / Emerfetamab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03224819 | Sep 2017 → Dec 2020 | acute myeloid leukemia | Amgen | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emerfetamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03224819 ↗ |
| Known as | AMG 673 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802264 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4802264 ↗ |
| Route | Intravenous | “Administered by intravenous (IV) infusion.” NCT03224819 ↗ |